- Home
- EE vs CVAC Comparison
EE vs CVAC Comparison
Compare EE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EE
- CVAC
- Stock Information
- Founded
- EE 2003
- CVAC 2000
- Country
- EE United States
- CVAC Germany
- Employees
- EE N/A
- CVAC N/A
- Industry
- EE Oil/Gas Transmission
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- EE Utilities
- CVAC Health Care
- Exchange
- EE Nasdaq
- CVAC Nasdaq
- Market Cap
- EE 825.4M
- CVAC 818.8M
- IPO Year
- EE 2022
- CVAC 2020
- Fundamental
- Price
- EE $26.00
- CVAC $3.17
- Analyst Decision
- EE Hold
- CVAC Buy
- Analyst Count
- EE 6
- CVAC 2
- Target Price
- EE $31.17
- CVAC $10.00
- AVG Volume (30 Days)
- EE 835.2K
- CVAC 690.2K
- Earning Date
- EE 05-07-2025
- CVAC 04-10-2025
- Dividend Yield
- EE 0.93%
- CVAC N/A
- EPS Growth
- EE 13.91
- CVAC N/A
- EPS
- EE 1.27
- CVAC 0.75
- Revenue
- EE $851,437,000.00
- CVAC $554,073,921.00
- Revenue This Year
- EE $4.96
- CVAC N/A
- Revenue Next Year
- EE $32.16
- CVAC $66.34
- P/E Ratio
- EE $20.39
- CVAC $4.29
- Revenue Growth
- EE N/A
- CVAC 895.54
- 52 Week Low
- EE $16.39
- CVAC $2.22
- 52 Week High
- EE $32.99
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- EE 42.69
- CVAC 54.64
- Support Level
- EE $24.00
- CVAC $3.06
- Resistance Level
- EE $26.75
- CVAC $3.02
- Average True Range (ATR)
- EE 1.30
- CVAC 0.19
- MACD
- EE 0.07
- CVAC 0.05
- Stochastic Oscillator
- EE 70.42
- CVAC 82.25
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.